003022 联泓新科
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入2,245,73145.93%6,337,5326,267,9146,777,5858,156,991
减:营业总成本2,038,83639.37%6,041,4086,190,9836,578,2677,472,526
    其中:营业成本1,722,39937.79%5,151,3125,233,6555,682,3546,507,510
               财务费用58,661107.86%119,89088,44586,929115,520
               资产减值损失(656)-71.03%(10,903)(7,444)(41,886)(12,277)
公允价值变动收益8532.65%441340486965
投资收益1,078894.75%4,14741,391(2,785)1,614
    其中:对联营企业和合营企业的投资收益9161,324.78%3,375(149)(485)(227)
营业利润206,127122.69%346,256317,880519,154860,334
利润总额205,430121.96%345,598301,464520,879857,866
减:所得税费用21,58018.35%28,12835,71464,646(16,030)
净利润183,849147.38%317,470265,749456,234873,895
减:非控股权益39,1281,243.99%11,75931,30710,1107,647
股东净利润144,721102.67%305,711234,443446,123866,248

市场价值指针
每股收益 (元) *0.110120.00%0.2300.1800.3300.650
每股派息 (元) *----0.0700.0600.0800.200
每股净资产 (元) *5.6823.79%5.5695.4235.3325.194
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容